Empowered Patient Podcast

Chris Hart, Co-Founder, CEO, and President of Creyon Bio, is focused on engineering drugs rather than just discovering them through serendipity and traditional methods.  Creyon is developing oligonucleotide medicines for rare and common diseases by applying AI and big data models of the molecular and genetic basis of diseases to develop safe and effective drugs more quickly.  Chris elaborates, "When we think about drug engineering versus drug discovery, we’re thinking about how we take this process that currently requires us to do trial-and-error identification of molecules that may be beneficial in the clinic to a place where we can say, can I build the right machinery, the right data, the right models, the right processes to go in and understand if I want to make this modulation within a cell, here’s the molecule that will do it and I can have confidence that it will be safe." "In terms of drug engineering and the type of drug engineering that Creyon does, what made starting Creyon the right thing to do and